Gene Editing Market Report: 2027-2031 Forecast, Technology and Partnering Opportunities by Application, Technology, Editing Setting, Customer, Product and Country - Strategic Analysis of 56 Companies

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2.1 Market Definition
2.2 Segments
2.3 Forecast Approach
2.4 Data Sources
2.5 Limitations
2.6 Authors

3.1 What is Gene Editing?
3.2 The CRISPR Example
3.3 Beyond Cutting: The Successors to CRISPR Nucleases
3.4 Chromosomes, Genes and Epigenetics
3.5 Delivery: Getting the Editor into the Cell
3.6 Gene Editing in Agriculture and Animals
3.7 The Gene Editing Industry
3.8 Perspective: Healthcare Spending

4.1 Global Market Overview by Country
4.2 Global Market by Application - Overview
4.3 Global Market by Technology - Overview
4.4 Global Market by Editing Setting - Overview
4.5 Global Market by Customer - Overview
4.6 Global Market by Product - Overview

5.1 From Research Tool to Medicine
5.2 Casgevy: The First Approved Gene-Edited Therapy
5.3 In Vivo Editing Reaches Phase 3
5.4 Other Approaches in the Clinic
5.5 Safety Events and Their Effects
5.6 Clinical Pipeline Table
5.7 Pipeline Milestones, 2027-2031

6.1 Beyond Human Therapy
6.2 CRISPR Diagnostics
6.3 Gene-Edited Crops
6.4 Gene-Edited Animals
6.5 Regulation of Edited Plants and Animals by Country
6.6 Outlook

7.1 Overview
7.2 Nucleases
7.3 Base Editing
7.4 Prime Editing
7.5 Epigenetic and RNA Editing
7.6 Large Insertions: Recombinases, Transposases and Bridge Editing
7.7 Delivery
7.8 Off-Target Assessment and Analytics
7.9 Software, Design and Screening Tools
7.10 Technology Outlook

8.1 The Largest Part of the Market
8.2 Guide RNA and Nucleic Acid Reagents
8.3 Cell Line Engineering and Engineered Models
8.4 Functional Genomics and Screening
8.5 Instruments
8.6 Services and CDMOs
8.7 Key Vendors
8.8 How Suppliers Compete
8.9 Demand Drivers and Risks

9.1 Overview: Three Regulatory Worlds
9.2 Human Therapies: United States
9.3 Human Therapies: Reimbursement in the United States
9.4 Human Therapies: Europe
9.5 Human Therapies: United Kingdom
9.6 Human Therapies: Asia and Other Markets
9.7 Agriculture: Gene-Edited Crops and Livestock
9.8 Implications for the Forecast

10.1 Intellectual Property
10.2 Litigation
10.3 Pricing

11.1 Overview
11.2 Regulation of Human Gene-Editing Therapies
11.3 Company Landscape
11.4 Demand: Thalassaemia, Rare Disease and Chronic Disease
11.5 Pricing and Reimbursement
11.6 Agricultural Gene Editing in China
11.7 Geopolitics and Cross-Border Business
11.8 Outlook and Implications for Global Companies

12.1 Deal Database
12.2 Deal Themes
12.3 Financing
12.4 Valuation Trends
12.5 Outlook for Deal-Making

13.1 Recent Developments - Importance and How to Use This Section
13.2 Intellia Reports Positive Phase 3 HAELO Results for Lonvo-z in Hereditary Angioedema
13.3 FDA Expands Casgevy Approval to Children Aged 2 and Older
13.4 FDA Issues Draft Guidance on the Plausible Mechanism Framework for Individualised Therapies
13.5 Prime Medicine Plans to Seek FDA Approval for Prime-Edited CGD Therapy
13.6 FDA Clears Prime Medicine's IND for PM647 in Alpha-1 Antitrypsin Deficiency
13.7 Beam Starts BEAM-302 Pivotal Cohort and Plans Risto-cel BLA
13.8 Intellia Pauses Dosing in Phase 3 nex-z Trials After Severe Liver Event
13.9 CRISPR Therapeutics' CTX310 Cuts Triglycerides and LDL in Phase 1
13.10 Perceptive Advisors Completes Acquisition of Synthego's Assets
13.11 Casgevy Uptake Accelerates as Infusions and Cell Collections Rise

14.1 Overview
14.2 Guide RNA
14.3 Editor mRNA and Protein
14.4 Lipid Nanoparticles
14.5 Viral and Virus-Like Delivery
14.6 Ex Vivo Cell Manufacturing
14.7 Conditioning and Treatment Centre Capacity
14.8 CDMOs and Outsourcing
14.9 Quality Control and Release Testing
14.10 Cost of Goods
14.11 Supply Chain Risks
14.12 Implications for Developers and Suppliers

15.1 Market Structure
15.2 Industry Structure: Players in a Dynamic Market
15.3 Therapy Developers by Editor Type and Stage
15.4 Leading Companies by Segment
15.5 Competitive Positioning
15.6 Estimated Competitive Tiers
15.7 Leading Companies
15.8 China Players
15.9 Exits, Restructurings and Consolidation
15.10 Outlook

16.1 Factors Driving Growth
16.2 Factors Limiting Growth
16.3 SWOT Analysis
16.4 Porter's Five Forces
16.5 Key Investment Risks
16.6 Investment Risk Matrix

17.1 Guidance for Executives, Marketing, Sales and Business Development
17.2 White-Space Opportunities
17.3 Partnering Strategy Guidance
17.4 Recommendations by Company Type
17.5 Guide for Management Consultants and Investment Advisors

18.1 Cell Line Engineering
18.2 Agriculture & Plants
18.3 Animal Models & Livestock
18.4 Cell Therapy
18.5 Gene Therapy
18.6 CRISPR Diagnostics
18.7 Research & Functional Genomics
18.8 Other

19.1 CRISPR-Cas Nuclease
19.2 Base Editing
19.3 Prime Editing
19.4 Epigenetic & RNA Editing
19.5 TALENs & ZFNs
19.6 Meganuclease & Other

20.1 In Vivo
20.2 Ex Vivo
20.3 In Vitro

21.1 Biopharma
21.2 Clinical & Hospital
21.3 Academic & Government
21.4 CROs & CDMOs
21.5 Agriculture & Other

22.1 Reagents & Kits
22.2 Engineered Cells & Models
22.3 Services
22.4 Instruments & Software

23.1 10x Genomics
23.2 Acceligen (Recombinetics)
23.3 Agilent Technologies
23.4 Aldevron (Danaher)
23.5 Allogene Therapeutics
23.6 Applied StemCell
23.7 Arbor Biotechnologies
23.8 Bayer Crop Science
23.9 Beam Therapeutics
23.10 Bio-Techne
23.11 Caribou Biosciences
23.12 Cellecta
23.13 Charles River Laboratories
23.14 Cibus
23.15 Corteva
23.16 CrisprBits
23.17 CRISPR Therapeutics
23.18 Cyagen Biosciences
23.19 Editas Medicine
23.20 EditCo Bio
23.21 ERS Genomics
23.22 GenScript
23.23 Genus plc (PIC)
23.24 Inari Agriculture
23.25 Integrated DNA Technologies (Danaher)
23.26 Intellia Therapeutics
23.27 Korro Bio
23.28 Locus Biosciences
23.29 Lonza
23.30 Mammoth Biosciences
23.31 MaxCyte
23.32 Merck KGaA (MilliporeSigma)
23.33 Metagenomi
23.34 nChroma Bio
23.35 Ohalo Genetics
23.36 Pairwise
23.37 Precision BioSciences
23.38 Prime Medicine
23.39 Regeneron Pharmaceuticals
23.40 Revvity
23.41 Sanatech Seed
23.42 Scope Biosciences
23.43 Scribe Therapeutics
23.44 Sherlock Biosciences (OraSure Technologies)
23.45 Synthego
23.46 Takara Bio
23.47 Tessera Therapeutics
23.48 Thermo Fisher Scientific
23.49 Tropic
23.50 Tune Therapeutics
23.51 Twist Bioscience
23.52 VedaBio
23.53 Vertex Pharmaceuticals
23.54 Verve Therapeutics (Eli Lilly)
23.55 Wave Life Sciences
23.56 YolTech Therapeutics

24.1 Abbreviations
24.2 Developments Archive
24.3 Report Limitations Restated

Table 1 Gene Editing Market Summary, 2026 and 2031
Table 2 Leading Gene-Editing Products, Programmes and Platforms
Table 3 Forecast Segments
Table 4 Main Types of Gene Editor
Table 5 The Base Pairs
Table 6 Main Methods of Delivering Gene Editors
Table 7 Main Types of Player in Gene Editing
Table 8 Global Market by Country
Table 9 Global Market by Application
Table 10 Global Market by Technology
Table 11 Global Market by Editing Setting
Table 12 Global Market by Customer
Table 13 Global Market by Product
Table 14 Selected Clinical Gene-Editing Programmes, October 2026
Table 15 Regulation of Gene-Edited Plants and Animals in Major Markets, October 2026
Table 16 Main Classes of Gene Editor
Table 17 Selected Suppliers of Gene Editing Tools, Reagents and Services
Table 18 Regulation and Payment of Gene-Editing Therapies by Jurisdiction
Table 19 Regulation of Gene-Edited Crops in Major Markets
Table 20 Pricing of Gene-Editing Therapies
Table 21 Selected Chinese Gene-Editing Therapy Companies
Table 22 Selected Deals in Gene Editing and Adjacent Fields, 2023-2026
Table 23 Therapy Developers by Editor Type and Stage
Table 24 Leading Companies by Segment
Table 25 Competitive Positioning of Leading Gene Editing Companies
Table 26 Estimated Competitive Tiers in Gene Editing
Table 27 Factors Driving Growth
Table 28 Factors Limiting Growth
Table 29 Investment Risk Matrix
Table 30 Recommendations by Company Type
Table 31 Cell Line Engineering by Country
Table 32 Agriculture & Plants by Country
Table 33 Animal Models & Livestock by Country
Table 34 Cell Therapy by Country
Table 35 Gene Therapy by Country
Table 36 CRISPR Diagnostics by Country
Table 37 Research & Functional Genomics by Country
Table 38 Other by Country
Table 39 CRISPR-Cas Nuclease by Country
Table 40 Base Editing by Country
Table 41 Prime Editing by Country
Table 42 Epigenetic & RNA Editing by Country
Table 43 TALENs & ZFNs by Country
Table 44 Meganuclease & Other by Country
Table 45 In Vivo by Country
Table 46 Ex Vivo by Country
Table 47 In Vitro by Country
Table 48 Biopharma by Country
Table 49 Clinical & Hospital by Country
Table 50 Academic & Government by Country
Table 51 CROs & CDMOs by Country
Table 52 Agriculture & Other by Country
Table 53 Reagents & Kits by Country
Table 54 Engineered Cells & Models by Country
Table 55 Services by Country
Table 56 Instruments & Software by Country

Figure 1 Key Graphic - Beyond the CRISPR Cut: Gene Editing Market by Technology, 2026 vs 2031
Figure 2 DNA Strands and Chromosomes
Figure 3 Karyogram of Human Chromosomes
Figure 4 Size of Various Genomes
Figure 5 Global Market Pareto Chart
Figure 6 Global Market by Application - Base vs. Final
Figure 7 Global Market by Application Base Year
Figure 8 Global Market by Application End Year
Figure 9 Application Share by Year
Figure 10 Application Segments Growth
Figure 11 Global Market by Technology - Base vs. Final
Figure 12 Global Market by Technology Base Year
Figure 13 Global Market by Technology End Year
Figure 14 Technology Share by Year
Figure 15 Technology Segments Growth
Figure 16 Global Market by Editing Setting - Base vs. Final
Figure 17 Global Market by Editing Setting Base Year
Figure 18 Global Market by Editing Setting End Year
Figure 19 Editing Setting Share by Year
Figure 20 Editing Setting Segments Growth
Figure 21 Global Market by Customer - Base vs. Final
Figure 22 Global Market by Customer Base Year
Figure 23 Global Market by Customer End Year
Figure 24 Customer Share by Year
Figure 25 Customer Segments Growth
Figure 26 Global Market by Product - Base vs. Final
Figure 27 Global Market by Product Base Year
Figure 28 Global Market by Product End Year
Figure 29 Product Share by Year
Figure 30 Product Segments Growth
Figure 31 Cell Line Engineering Growth
Figure 32 Agriculture & Plants Growth
Figure 33 Animal Models & Livestock Growth
Figure 34 Cell Therapy Growth
Figure 35 Gene Therapy Growth
Figure 36 CRISPR Diagnostics Growth
Figure 37 Research & Functional Genomics Growth
Figure 38 Other Growth
Figure 39 CRISPR-Cas Nuclease Growth
Figure 40 Base Editing Growth
Figure 41 Prime Editing Growth
Figure 42 Epigenetic & RNA Editing Growth
Figure 43 TALENs & ZFNs Growth
Figure 44 Meganuclease & Other Growth
Figure 45 In Vivo Growth
Figure 46 Ex Vivo Growth
Figure 47 In Vitro Growth
Figure 48 Biopharma Growth
Figure 49 Clinical & Hospital Growth
Figure 50 Academic & Government Growth
Figure 51 CROs & CDMOs Growth
Figure 52 Agriculture & Other Growth
Figure 53 Reagents & Kits Growth
Figure 54 Engineered Cells & Models Growth
Figure 55 Services Growth
Figure 56 Instruments & Software Growth